Aging in 1000 healthy midlife adults: Phase 52 of the Dunedin Study

点击翻译按钮获取中文摘要

PROJECT SUMMARY - NO CHANGES FROM PARENT AWARD The overarching goal of our research program is to discover why some people age earlier and faster than others, and what might be done to prevent this. Increasingly, prevention-minded gerontologists and geroscientists look to midlife as the life stage offering a propitious opportunity to prevent or delay the multiple diseases that shrink older adults’ health span. But because most studies of aging have enrolled participants well past midlife, and most studies of younger adults have not measured aging as a process of change over time, there is surprisingly little basic knowledge about aging during midlife. Our research program uniquely fills this gap. This is a competing renewal proposal to follow up at age 52 a cohort of all 1037 infants born in one city in one year and exhaustively studied ever since: the Dunedin Longitudinal Study. Some cohort members are becoming biologically older than their peers as they pass through midlife, others remain biologically younger. The proposed follow-up will allow us to quantify how fast or slowly each cohort member is aging in each of 8 different domains: the pace of biological aging, functional aging, facial aging, social aging, sexual aging, inflammatory aging, microvascular aging, and cognitive aging (Aim 1A). These 8 domains are typically studied by different scientific disciplines in silos, but we will study them together in one cohort to attract scientific recognition to the great heterogeneity within the whole-person experience of aging. We will develop a measure of each of the 8 kinds of aging, by modelling 3 or more waves of data on each. Three data waves are the minimum requirement to disentangle each person’s decline (aging-related decline, how people have changed; their slope) from their level (initial health, where people started; their intercept). Studies with fewer than 3 waves conflate decline over the years (aging) with low scores present since earlier life (not aging). The proposed follow-up at age 52 is necessary to add the essential 3rd midlife wave for this cohort of participants. This follow-up will create an unprecedented unique dataset. To amplify scientific progress, we will deliver to the research community a reliable, valid, open-access DNA-methylation version of each of the 8 new measures of how rapidly a person has been aging (Aim 1B). To evaluate generalizability of findings for under-represented ethnic-groups, we will export the 8 new DNA-methylation measures to Black and Latinx cohorts with methylation, where we have established collaborations to study the pace of aging. We will further generate new knowledge about the early-life antecedents of each kind of aging (Aim 2). We will also generate new knowledge about the risk each of the 8 kinds of aging poses for late-life disease (Aim 3). This involves testing the hypothesis that fast-aging individuals show compromised capacity at age 52 to mount a healthy immune response in vitro. It also involves testing the hypothesis that fast-aging individuals have elevated scores at age 52 on blood biomarkers for Alzheimers disease.